Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.

Human hepatic microsomes were used to investigate the carboxylesterase-mediated bioactivation of CPT-11 to the active metabolite, SN-38. SN-38 formation velocity was determined by HPLC over a concentration range of 0.25-200 microM CPT-11. Biphasic Eadie Hofstee plots were observed in seven donors, suggesting that two isoforms catalyzed the reaction. Analysis by nonlinear least squares regression gave KM estimates of 129-164 microM with a Vmax of 5.3-17 pmol/mg/min for the low affinity isoform. The high affinity isoform had KM estimates of 1.4-3.9 microM with Vmax of 1.2-2.6 pmol/mg/min. The low KM carboxylesterase may be the main contributor to SN-38 formation at clinically relevant hepatic concentrations of CPT-11. Using standard incubation conditions, the effects of potential inhibitors of carboxylesterase-mediated CPT-11 hydrolysis were evaluated at concentrations >/= 21 microM. Positive controls bis-nitrophenylphosphate (BNPP) and physostigmine decreased CPT-11 hydrolysis to 1.3-3.3% and 23% of control values, respectively. Caffeine, acetylsalicylic acid, coumarin, cisplatin, ethanol, dexamethasone, 5-fluorouracil, loperamide, and prochlorperazine had no statistically significant effect on CPT-11 hydrolysis. Small decreases were observed with metoclopramide (91% of control), acetaminophen (93% of control), probenecid (87% of control), and fluoride (91% of control). Of the compounds tested above, based on these in vitro data, only the potent inhibitors of carboxylesterase (BNPP, physostigmine) have the potential to inhibit CPT-11 bioactivation if administered concurrently. The carboxylesterase-mediated hydrolysis of alpha-naphthyl acetate (alpha-NA) was used to determine whether CPT-11 was an inhibitor of hydrolysis of high turnover substrates of carboxylesterases. Inhibition of alpha-NA hydrolysis by CPT-11 was determined relative to positive controls BNPP and NaF. Incubation with microsomes pretreated with CPT-11 (80-440 microM) decreased alpha-naphthol formation to approximately 80% of control at alpha-NA concentrations of 50-800 microM. The inhibitors BNPP (360 microM) and NaF (500 microM) inhibited alpha-naphthol formation to 9-10% of control and to 14-20% of control, respectively. Therefore, CPT-11-sensitive carboxylesterase isoforms may account for only 20% of total alpha-NA hydrolases. Thus, CPT-11 is unlikely to significantly inhibit high turnover, nonselective substrates of carboxylesterases.

[1]  H. Hakusui,et al.  Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. , 1995, Biological & pharmaceutical bulletin.

[2]  B. Hammock,et al.  The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. , 1996, Cancer research.

[3]  N. Kemeny,et al.  Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[5]  A. Y. Lu,et al.  Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. , 1972, Biochemical and biophysical research communications.

[6]  M. Ratain,et al.  Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital , 1997, Cancer Chemotherapy and Pharmacology.

[7]  D. Petersen,et al.  Purification and characterization of two rat liver microsomal carboxylesterases (hydrolase A and B). , 1994, Archives of biochemistry and biophysics.

[8]  K. Thoma,et al.  [Relationships between manufacturing parameters and pharmaceutical-technological requirements of biodegradable microparticles. 2. Preparation of injectable microparticles in biodegradable polyester]. , 1992, Die Pharmazie.

[9]  N. Saijo,et al.  Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. , 1994, Journal of the National Cancer Institute.

[10]  T. Ohira,et al.  Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11 , 1995, Japanese journal of cancer research : Gann.

[11]  Daniel M. Bender,et al.  Quantitative kinetic assays for glutathione S-transferase and general esterase in individual mosquitoes using an EIA reader , 1989 .

[12]  J. Robert,et al.  Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. , 1998, Cancer research.

[13]  T. Burke,et al.  The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.

[14]  T. J. Yang,et al.  Differential sodium fluoride sensitivity of alpha-naphthyl acetate esterase in human, bovine, canine, and murine monocytes and lymphocytes. , 1991, Experimental hematology.

[15]  J. Rask-Madsen,et al.  Clinical Pharmacokinetics of Drugs Used in the Treatment of Gastrointestinal Diseases (Part I) , 1990, Clinical pharmacokinetics.

[16]  T. Yoshimoto,et al.  CPT-11 converting enzyme from rat serum: purification and some properties. , 1991, Journal of pharmacobio-dynamics.

[17]  Jones Sf,et al.  Topoisomerase I inhibitors: topotecan and irinotecan. , 1996, Cancer practice.

[18]  J. Robert,et al.  Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. , 1996, Biochemical pharmacology.

[19]  J. Suttie,et al.  Fluoride inhibition of rat liver microsomal esterases. , 1974, The Journal of biological chemistry.

[20]  S. Culine,et al.  Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Tunek,et al.  Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Kensuke Matsumoto,et al.  Production of SN-38, a Main Metabolite of the Camptothecin Derivative CPT-11, and Its Species and Tissue Specificities. , 1991 .

[23]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[24]  P. Hérait,et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.

[25]  J. Robert,et al.  The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  T. Satoh,et al.  Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. , 1994, Biological & pharmaceutical bulletin.

[27]  D. Kroetz,et al.  Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. , 1993, Biochemistry.

[28]  T. Satoh,et al.  Interindividual variation in carboxylesterase levels in human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[29]  S. Pond,et al.  Purification and characterization of two human liver carboxylesterases. , 1989, The International journal of biochemistry.

[30]  B. Yan,et al.  Regulation of two rat liver microsomal carboxylesterase isozymes: species differences, tissue distribution, and the effects of age, sex, and xenobiotic treatment of rats. , 1994, Archives of biochemistry and biophysics.

[31]  J. Verweij,et al.  Topoisomerase I inhibitors: topotecan and irenotecan. , 1994, Cancer treatment reviews.

[32]  R. Herrmann,et al.  Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. , 1988, Cancer research.

[33]  U. Kaveeshwar,et al.  Difference in the inhibition of plasma carboxylesterase activity by metoclopramide in humans and laboratory animals. , 1992, Die Pharmazie.